| Symbol | PTGX |
|---|---|
| Name | PROTAGONIST THERAPEUTICS, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA 94560-1160 |
| Telephone | (510) 474-0170 |
| Fax | — |
| — | |
| Website | https://www.protagonist-inc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001377121 |
| Description | Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidate to address medical needs. The Company operates and manages its business as one operating segment. Additional info from NASDAQ: |
Director Waddill William D. 🟡 adjusted position in 9.0K shares (1 derivative) of Protagonist Therapeutics, Inc (PTGX) at $117.94 ($1.4M) Transaction Date: Jun 23, 2026 | Filing ID: 077761
Read more📋 WILLIAM WADDILL (Director) plans to sell 9K shares of PROTAGONIST THERAPEUTICS, INC. (at $115.03 each, total $1.0M) Filed: Jun 23, 2026 | ID: 006422
Read moreDirector Waddill William D. 🟡 adjusted position in 9.0K shares (2 derivative) of Protagonist Therapeutics, Inc (PTGX) at $107.68 ($1.2M) Transaction Date: Jun 10, 2026 | Filing ID: 073049
Read more📋 WILLIAM WADDILL (Director) plans to sell 9K shares of PROTAGONIST THERAPEUTICS, INC. (at $105.87 each, total $953K) Filed: Jun 10, 2026 | ID: 005894
Read moreDirector Waddill William D. 🟡 adjusted position in 9.0K shares (1 derivative) of Protagonist Therapeutics, Inc (PTGX) at $99.64 ($1.1M) Transaction Date: May 29, 2026 | Filing ID: 069047
Read moreNew Form 4/A - Protagonist Therapeutics, Inc <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001104659-26-061476 <b>Size:</b> 9 KB
Read moreDirector PATEL DINESH V PH D 🟡 adjusted position in 75.0K shares (1 derivative) of Protagonist Therapeutics, Inc (PTGX) at $100.12 ($10.7M) Transaction Date: May 12, 2026 | Filing ID: 059591
Read more📋 Dinesh Patel (CEO) plans to sell 75K shares of Protagonist Therapeutics, Inc. (at $103.50 each, total $7.8M) Filed: May 12, 2026 | ID: 000430
Read moreNew Form SCHEDULE 13G - Protagonist Therapeutics, Inc <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000093751-26-000283 <b>Size:</b> 8 KB
Read moreDirector Giraudo Bryan 🟡 adjusted position in 59.1K shares (2 derivative) of Protagonist Therapeutics, Inc (PTGX) at $100.14 ($6.4M) Transaction Date: May 07, 2026 | Filing ID: 058860
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07153146 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healt… | Phase1 | Healthy Volunteer | Recruiting | 2025-10-07 | 2026-06-15 | ClinicalTrials.gov |
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With… | Phase3 | Polycythemia Vera | Active_Not_Recruiting | 2024-01-22 | 2027-04-01 | ClinicalTrials.gov |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | Phase3 | Polycythemia Vera | Active_Not_Recruiting | 2022-04-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT04819620 | Pharmacokinetics of PN-232 in Healthy Volunteers | Phase1 | Healthy Subjects | Completed | 2021-05-13 | 2022-06-16 | ClinicalTrials.gov |
| NCT04524221 | PTG-100 for Patients With Celiac Disease | Phase1 | Celiac Disease | Completed | 2021-02-26 | 2022-04-03 | ClinicalTrials.gov |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit | Phase2 | Polycythemia Vera | Completed | 2021-02-02 | 2023-03-15 | ClinicalTrials.gov |
| NCT04621630 | Pharmacokinetics of PN-235 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2020-11-12 | 2021-10-13 | ClinicalTrials.gov |
| NCT04516382 | Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy … | Phase1 | Healthy Volunteers | Completed | 2020-09-14 | 2021-06-30 | ClinicalTrials.gov |
| NCT04504383 | PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) | Phase2 | Ulcerative Colitis Chronic Moderate | Completed | 2020-08-05 | 2023-02-16 | ClinicalTrials.gov |
| NCT04202965 | PTG-300 in Subjects With Hereditary Hemochromatosis | Phase2 | Hereditary Hemochromatosis | Completed | 2020-03-19 | 2022-02-15 | ClinicalTrials.gov |
| NCT04057040 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | Phase2 | Polycythemia Vera | Completed | 2019-10-01 | 2024-06-17 | ClinicalTrials.gov |
| NCT04054921 | Safety Study for Beta Thalassemia Subjects on PTG-300 | Phase2 | β-thalassemia | Completed | 2019-05-10 | 2020-07-31 | ClinicalTrials.gov |
| NCT03802201 | Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Th… | Phase2 | β-thalassemia | Completed | 2018-12-19 | 2020-07-31 | ClinicalTrials.gov |
| NCT02895100 | Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulc… | Phase2 | Ulcerative Colitis | Terminated | 2016-12-01 | 2018-03-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04524221 |
| PTG-100 | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04524221 |
| Placebo | Other | Phase PHASE2 | Polycythemia Vera | COMPLETED | NCT04057040 |
| PTG-300 | Other | Phase PHASE2 | Polycythemia Vera | COMPLETED | NCT04057040 |
| PTG-300 | Other | Phase PHASE2 | β-thalassemia | COMPLETED | NCT04054921 |
| PTG-300 | Other | Phase PHASE2 | β-thalassemia | COMPLETED | NCT03802201 |
| PTG-300 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04516382 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04621630 |
| PN-235 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04621630 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04819620 |
| PN-232 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04819620 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis Chronic Moderate | COMPLETED | NCT04504383 |
| PN-943 | Other | Phase PHASE2 | Ulcerative Colitis Chronic Moderate | COMPLETED | NCT04504383 |
| PTG-300 | Other | Phase PHASE2 | Polycythemia Vera | COMPLETED | NCT04767802 |
| Open-label rusfertide | Other | Phase PHASE3 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT06033586 |
| Rusfertide | Other | Phase PHASE3 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05210790 |
| Placebo | Other | Phase PHASE3 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05210790 |
| PTG-300 | Other | Phase PHASE2 | Hereditary Hemochromatosis | COMPLETED | NCT04202965 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT02895100 |
| PTG-100 | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT02895100 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07153146 |
| PN-881 Oral Tablet | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07153146 |
| PN-881 Oral Solution | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07153146 |
| PN-881 Oral Tablet | DRUG | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07153146 |
| PN-881 Oral Solution | DRUG | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07153146 |
| Open-label rusfertide | DRUG | Phase PHASE3 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT06033586 |
| Rusfertide | DRUG | Phase PHASE3 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05210790 |
| PN-232 | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04819620 |
| PN-235 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04621630 |
| PN-943 | DRUG | Phase PHASE2 | Ulcerative Colitis Chronic Moderate | COMPLETED | NCT04504383 |
| PTG-300 | DRUG | Phase PHASE2 | Polycythemia Vera | COMPLETED | NCT04767802 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07153146 |
| PTG-100 | DRUG | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04524221 |